US Edition
Linvoseltamab Offers Hope for Patients With Refractory Multiple Myeloma: Sundar Jagannath, MBBS
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Linvoseltamab Offers Hope for Patients With Refractory Multiple Myeloma: Sundar Jagannath, MBBS
The FDA’s approval of linvoseltamab for adults with heavily pretreated relapsed/refractory multiple myeloma marks a significant advance, with Sundar Jagannath, MBBS, emphasizing its high response rates, manageable dosing schedule, and reduced treatment burden.
Expert: FDA-Approved Linvoseltamab Delivers Deep Responses, Offering New Hope For Older Patients With MM
Sundar Jagannath, MD, MBBS, explains how linvoseltamab showed strong efficacy and tolerability in the LINKER-MM1 trial, making it an appealing option for older patients with relapsed or refractory multiple myeloma (MM).
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
